A Seat At The Drug Safety Table: Public Citizen’s Wolfe Joins FDA Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
Long-time industry critic Sidney Wolfe will serve as permanent member of the Drug Safety and Risk Management panel for the next four years.
You may also be interested in...
Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote
Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.
FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.
FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.